keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab

keyword
https://www.readbyqxmd.com/read/28319066/nucleus-accumbens-associated-protein-1-promotes-glycolysis-and-survival-of-hypoxic-tumor-cells-via-the-hdac4-hif-1%C3%AE-axis
#1
Y Zhang, Y-J Ren, L-C Guo, C Ji, J Hu, H-H Zhang, Q-H Xu, W-D Zhu, Z-J Ming, Y-S Yuan, X Ren, J Song, J-M Yang
Nucleus accumbens-associated protein-1 (NAC1), a nuclear factor of the BTB/POZ gene family, has emerging roles in cancer. In this study, we identified the NAC1-HDAC4-HIF-1α axis as an important pathway in regulating glycolysis and hypoxic adaptation in tumor cells. We show that nuclear NAC1 binds to histone deacetylase type 4 (HDAC4), hindering phosphorylation of HDAC4 at Ser(246) and preventing its nuclear export that leads to cytoplasmic degradation of the deacetylase. Accumulation of HDAC4 in the nuclei results in an attenuation of HIF-1α acetylation, enhancing the stabilization and transcriptional activity of HIF-1α and strengthening adaptive response of cells to hypoxia...
March 20, 2017: Oncogene
https://www.readbyqxmd.com/read/28315518/real-world-outcomes-of-anti-vegf-treatment-for-retinal-vein-occlusion-in-portugal
#2
Sara Vaz-Pereira, Inês P Marques, João Matias, Filipe Mira, Lígia Ribeiro, Rita Flores
PURPOSE: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. METHODS: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment...
February 28, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315202/validation-of-bevacizumab-therapy-effect-on-colon-cancer-subtypes-by-using-whole-body-imaging-in-mice
#3
Ivan Vuletic, Kedi Zhou, Hui Li, Huichen Bai, Xiangxi Meng, Sihao Zhu, Yichen Ding, Jun Li, Hongfang Sun, Qiushi Ren
PURPOSE: Preclinical imaging offers a useful tool for monitoring cancer biological behavior and therapy in vivo without the necessity of animal surgery. The following paper describes our examination of tumor progress and anti-angiogenic therapy with Bevacizumab on colon cancer subtypes (SW480 and SW620) by using different non-invasive real-time in vivo imaging techniques. PROCEDURES: Color Doppler ultrasound imaging (CDUI) was used to observe the formation of new blood vessels; a homemade fluorescence reflectance imaging (FRI) apparatus was mainly used to test the difference in VEGFR2 expression between the tumor subtypes...
March 17, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28314990/an-apparent-clinical-pharmacokinetic-drug-drug-interaction-between-bevacizumab-and-the-anti-placental-growth-factor-monoclonal-antibody-ro5323441-via-a-target-trapping-mechanism
#4
Ka Wang, Franziska Schaedeli Stark, Tilman Schlothauer, Angelika Lahr, Valerie Cosson, Jianguo Zhi, Kai Habben, Jean Tessier, Eginhard Schick, Roland F Staack, Oliver Krieter
PURPOSE: RO5323441 is a humanized anti-placental growth factor (PlGF) monoclonal antibody that has shown preclinical activity in several cancer models. The objective of this analysis is to examine the pharmacokinetic (PK) results from four Phase I studies that have been conducted with RO5323441 (n = 61) and to report an apparent drug-drug interaction observed when RO5323441 was administered in combination with bevacizumab. METHODS: The four Phase I studies were a multiple-ascending dose study in 23 patients with solid tumors (Study 1), an open-label study in seven patients with colorectal/ovarian cancer (Study 2), a sorafenib combination study in nine patients with hepatocellular carcinoma (Study 3), and a bevacizumab combination study in 22 patients with recurrent glioblastoma (Study 4)...
March 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28314323/bevacizumab-combined-with-chemotherapy-in-children-affected-by-hepatocellular-carcinoma-a-single-center-experience
#5
Maria Debora DE Pasquale, Jean de Ville de Goyet, Lidia Monti, Chiara Grimaldi, Alessandro Crocoli, Aurora Castellano
BACKGROUND: Hepatocellular carcinoma (HCC) is very rare in children and is traditionally associated with a poor prognosis because many patients are not amenable to conventional resection, even in the absence of metastatic disease. For patients with locally advanced or metastatic tumors, conventional chemotherapy appears to offer limited survival benefits. PATIENTS AND METHODS: We report a case series of five consecutive pediatric patients with HCC who were treated with bevacizumab along with conventional platinum-based chemotherapy...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314310/first-line-bevacizumab-and-paclitaxel-for-her2-negative-metastatic-breast-cancer-a-french-retrospective-observational-study
#6
Veronique Dieras, Simona Pop, Frederique Berger, Marie-Eglantine Dujaric, Philippe Beuzeboc, Laurence Escalup, François Clement Bidard, Paul Henri Cottu, Christophe LE Tourneau, Sophie Piperno-Neumann, Valerie Laurence, Mathieu Robain, Bernard Asselain, Jean-Yves Pierga
AIM: To assess outcomes in patients treated with first-line bevacizumab-containing therapy for human epidermal growth factor receptor (HER)2-negative metastatic breast cancer (mBC) at a single centre with a homogenous standard-of-care. PATIENTS AND METHODS: Information on patient and disease characteristics, efficacy, and safety was extracted from computer-based records of all patients receiving first-line bevacizumab-paclitaxel at the Curie Institute, Paris, France, between 2008 and 2011...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314295/development-and-applicability-of-integrative-tumor-response-assays-for-metastatic-colorectal-cancer
#7
Yong Sik Yoon, Chan Wook Kim, Seon Ae Roh, Dong Hyung Cho, Tae Won Kim, Moon Bo Kim, Jin Cheon Kim
AIM: The present study investigated how well the results of integrative tumor-response assay (ITRA) compared to those of clinical response to chemotherapy in patients with metastatic colorectal cancer (CRC). PATIENTS AND METHODS: A total of 129 patients with metastatic CRC were prospectively enrolled. ITRA consisted of two sequential histoculture drug-response assays (HDRAs). First-stage HDRAs were performed using 5-fluorouracil with leucovorin and oxaliplatin (FX), or with irinotecan (FR)...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28306392/effect-of-syringe-design-on-the-accuracy-and-precision-of-intravitreal-injections-of-anti-vegf-agents
#8
Elad Moisseiev, Jolene Rudell, Eric V Tieu, Glenn Yiu
PURPOSE: To evaluate the accuracy and precision of different syringe designs for intravitreal injection of anti-VEGF agents. METHODS: Volume output was measured from three syringe designs-1) 1.0 mL tuberculin syringe, 2) 1.0 mL syringe with low dead space plunger, and 3) 0.5 mL low-volume syringe-to deliver 50 µL of bevacizumab, ranibizumab, or aflibercept, each repeated four times by three different physicians for 108 total simulated injections. Volume output was calculated from difference in syringe weight before and after expelling the drug...
March 17, 2017: Current Eye Research
https://www.readbyqxmd.com/read/28303751/vasoactive-peptides-associate-with-treatment-outcome-ofbevacizumab-containing-therapy-in-metastatic-colorectal-cancer
#9
Helga Hagman, Pär-Ola Bendahl, Olle Melander, Jan Sundberg, Anders Johnsson, Mattias Belting
BACKGROUND: Hypertension is a common early adverse event of anti-angiogenic treatment of cancer and may associate with treatment response. However, blood pressure measurement as a surrogate response biomarker has methodological limitations, and predictive biomarkers of angiogenesis inhibitors are lacking. In disease associated with hypertension, vasoactive peptides have been linked to cardiovascular pressure load. Here, we have explored potential associations between circulating levels of vasoactive peptides and tumor response during bevacizumab-containing treatment of colorectal cancer...
March 17, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28303729/case-of-glioblastoma-patient-treated-with-tumor-treating-fields-therapy-at-recurrence-degenerating-to-sarcoma
#10
Pejman Majd, Daniel E O'Connell, Ronald C Kim, Daniela A Bota, Jose A Carrillo
Optune(®) treatment is a US FDA-approved treatment for glioblastoma (GBM) that employs alternating electric fields. Tumor treating field (TTF) therapy can exert its effects on GBM via cell cycle mitosis disruption and cytokinesis. We describe a patient with recurrent GBM who had disease progression following standard surgical treatment and concomitant chemoradiotherapy, and was found to have sarcomatous transformation after initiation of TTF therapy with bevacizumab. Upon tumor progression, repeat surgical resection revealed transformation into a GFAP-negative, reticulin-positive sarcoma with rhabdomyoid features...
March 17, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28301639/association-of-repeated-intravitreous-bevacizumab-injections-with-risk-for-glaucoma-surgery
#11
Brennan D Eadie, Mahyar Etminan, Bruce C Carleton, David A Maberley, Frederick S Mikelberg
Importance: Intravitreous injections of anti-vascular endothelial growth factor (VEGF) agents are associated with a sustained increase in intraocular pressure. This sustained elevated intraocular pressure could lead to higher rates of glaucoma surgery to lower this pressure. Objective: To determine the risk of glaucoma surgery following repeated intravitreous bevacizumab injections. Design, Setting, Participants: This nested, case-control study acquired and analyzed data from large, population-based, linked health databases supported by the British Columbia Ministry of Health in Canada...
March 16, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28301412/large-silicone-droplets-after-intravitreal-bevacizumab-avastin
#12
Robert L Avery, Alessandro A Castellarin, Dilsher S Dhoot, Dante J Pieramici, Maʼan A Nasir, Nathan C Steinle, Logan P Avery, Gabriel M Gordon
PURPOSE: Despite its off-label status, intravitreal bevacizumab is the most commonly used intraocular anti-vascular endothelial growth factor agent. Regulation of compounding pharmacies has recently increased to make compounded pharmaceuticals safer. Despite these changes, a marked increase in symptomatic, large silicone oil droplets following intravitreal bevacizumab injections was noticed. METHODS: Retrospective chart review was performed. Within a single private practice, patients who were noted to have large or symptomatic silicone oil bubbles after an intravitreal injection were reviewed...
March 15, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28301410/allergic-reaction-upon-intravitreal-administration-of-anti-vascular-endothelial-growth-factor-agents
#13
Gavin G Meredith, Paul A Schkade, Brian C Joondeph
PURPOSE: To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization. METHODS: Clinical case report. RESULTS: Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept. CONCLUSION: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin...
March 15, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28299879/how-accurate-are-medical-oncologists-impressions-of-management-of-metastatic-colorectal-cancer-in-australia
#14
Lewis Au, Natalie Turner, Hui-Li Wong, Kathryn Field, Belinda Lee, David Boadle, Prasad Cooray, Deme Karikios, Suzanne Kosmider, Lara Lipton, Louise Nott, Phillip Parente, Jeanne Tie, Ben Tran, Rachel Wong, Desmond Yip, Jeremy Shapiro, Peter Gibbs
AIM: Current efforts to understand patient management in clinical practice are largely based on clinician surveys with uncertain reliability. The TRACC (Treatment of Recurrent and Advanced Colorectal Cancer) database is a multisite registry collecting comprehensive treatment and outcome data on consecutive metastatic colorectal cancer (mCRC) patients at multiple sites across Australia. This study aims to determine the accuracy of oncologists' impressions of real-word practice by comparing clinicians' estimates to data captured by TRACC...
March 16, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28299498/evaluation-of-vitreoretinal-interface-changes-in-patients-receiving-intravitreal-anti-vegf-therapy
#15
Vartika Kinra, Satvir Singh, Sumeet Khanduja, Manisha Nada
PURPOSE: To study the effects of repeated intravitreal injection of anti-VEGF drug bevacizumab on the vitreoretinal interface (VRI). METHODS: Patients undergoing intravitreal injection of bevacizumab were enrolled. Eyes with media haze, uveitis, high myopia, history of cataract surgery or laser capsulotomy in last 6 months and complicated pseudophakia were excluded. VRI evaluation was done monthly for a minimum of 6 months. The nature and timing of the change(s) event was recorded...
March 15, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28299006/characteristics-of-macular-edema-in-behcet-disease-after-intravitreal-bevacizumab-injection
#16
Fariba Ghassemi, Sohrab Afshari Mirak, Hormoz Chams, Siamak Sabour, Mehdi Nilli Ahmadabadi, Fereidoun Davatchi, Farhad Shahram
PURPOSE: To investigate the effect of intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to Behcet's disease. METHODS: This prospective case series included 15 patients with bilateral ME due to Behcet's disease. Intravitreal bevacizumab was injected into the more severely involved eye; the contralateral eye was evaluated as the control. Patients were followed up with comprehensive ocular examination, optical coherence tomography, and fluorescein angiography (FA) for a minimum of 6 months by a single ophthalmologist...
January 2017: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/28299000/chorioretinal-coloboma-complications-retinal-detachment-and-choroidal-neovascular-membrane
#17
Rehan M Hussain, Ashkan M Abbey, Ankoor R Shah, Kimberly A Drenser, Michael T Trese, Antonio Capone
PURPOSE: To report the chorioretinal coloboma, and its association with increased risk of retinal detachment (RD) and choroidal neovascularization (CNV). METHODS: This retrospective case series included eyes with chorioretinal coloboma diagnosed between 1995 and 2014 with a focus on RD and CNV as related complications. Cases of CNV were managed with laser photocoagulation or intravitreal injection of bevacizumab. For eyes with CNV, therapeutic success was defined as resolution of the subretinal hemorrhage on fundus examination and resolution of the subretinal and intraretinal fluid on optical coherence tomography (OCT)...
January 2017: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/28298545/homeobox-b9-mediates-resistance-to-anti-vegf-therapy-in-colorectal-cancer-patients
#18
Carmine Carbone, Geny Piro, Francesca Simionato, Francesca Ligorio, Chiara Cremolini, Fotios Loupakis, Greta Alì, Daniele Rossini, Valeria Merz, Raffaela Santoro, Camilla Zecchetto, Marco Zanotto, Federica Di Nicolantonio, Alberto Bardelli, Gabriella Fontanini, Giampaolo Tortora, Davide Melisi
PURPOSE: The identification of predictive biomarkers for antiangiogenic therapies remains an unmeet need. We hypothesized that the transcription factor Homeobox B9 (HOXB9) could be responsible for the tumor resistance to the anti-VEGF agent bevacizumab. EXPERIMENTAL DESIGN: HOXB9 expression and activation were measured in eight models of colorectal and pancreatic cancer with different resistance to bevacizumab. Serum levels of Angiopoietin-like Protein (Angptl)2, CXC receptor ligand (CXCL)1, interleukin(IL)8, and Transforming Growth Factor (TGF)β1 in tumor-bearing mice were measured by multiplex xMAP technology...
March 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28297041/fluorescein-angiography-versus-optical-coherence-tomography-angiography-in-macular-telangiectasia-type-i-treated-with-bevacizumab-therapy
#19
Nicolas A Yannuzzi, Ninel Z Gregori, Luiz Roisman, Nisha Gupta, Brian E Goldhagen, Raquel Goldhardt
This is a report of microvascular changes seen on fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) in a 47-year-old man with macular telangiectasia Type 1 (MacTel1) after a 7-year bevacizumab (Avastin; Genentech, South San Francisco, CA) treatment course. OCTA allowed for clear visualization of most telangiectasias and aneurysms in the deep capillary plexus, with only few microvascular dilatations in the superficial plexus. In addition, areas of capillary dropout in the superficial and deep vascular plexa located near telangiectasias were documented on OCTA...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28297039/reactivation-of-retinopathy-of-prematurity-three-years-after-treatment-with-bevacizumab
#20
Amir R Hajrasouliha, Jose M Garcia-Gonzales, Michael J Shapiro, Hawke Yoon, Michael P Blair
Although intravitreal injection of anti-vascular endothelial growth factor agents (IVA) can induce rapid regression of retinopathy of prematurity (ROP), late reactivation of the ROP can occur in the form of tractional retinal detachment (TRD) from contracted recurrent extraretinal fibrovascular proliferation. The authors report a case of bilateral TRD for recurrent ROP in a 3-year-old, which is the latest-reported reactivation to date. The authors propose that persistent avascular retina in eyes that have undergone IVA for ROP receive laser ablation to prevent late recurrences...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
1763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"